These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22768658)

  • 21. Decreased GH dose after the catch-up growth period maintains metabolic outcome in short prepubertal children with and without classic GH deficiency.
    Decker R; Albertsson-Wikland K; Kriström B; Halldin M; Dahlgren J
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):407-15. PubMed ID: 22417085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indications for growth hormone therapy in children.
    Kirk J
    Arch Dis Child; 2012 Jan; 97(1):63-8. PubMed ID: 21540481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
    Tauber M; Jaquet D; Jesuran-Perelroizen M; Petrus M; Bertrand AM; Coutant R;
    Patient Prefer Adherence; 2013; 7():455-62. PubMed ID: 23737664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to growth hormone therapy: a practical approach.
    Bozzola M; Pagani S; Iughetti L; Maffeis C; Bozzola E; Meazza C
    Horm Res Paediatr; 2014; 81(5):331-5. PubMed ID: 24714410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices.
    Pollock RF; Kappelgaard AM; Seitz L
    Expert Opin Drug Deliv; 2015 Mar; 12(3):353-60. PubMed ID: 25614081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
    Brearley C; Priestley A; Leighton-Scott J; Christen M
    BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency: A post-marketing, multicenter, observational study.
    Ishii H; Shimatsu A; Nishinaga H; Murai O; Chihara K
    Growth Horm IGF Res; 2017 Oct; 36():36-43. PubMed ID: 28923784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy.
    Gau M; Takasawa K
    J Pediatr Endocrinol Metab; 2017 Aug; 30(9):989-993. PubMed ID: 28771439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device.
    Loche S; Salerno M; Garofalo P; Cardinale GM; Licenziati MR; Citro G; Caruso Nicoletti M; Cappa M; Longobardi S; Maghnie M; Perrone R
    J Endocrinol Invest; 2016 Dec; 39(12):1419-1424. PubMed ID: 27406716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.
    Conway GS; Szarras-Czapnik M; Racz K; Keller A; Chanson P; Tauber M; Zacharin M;
    Eur J Endocrinol; 2009 Jun; 160(6):899-907. PubMed ID: 19324976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
    Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.
    Drent ML; Jakobsdottir S; van Wijk JAE; Oostdijk W; Wit JM
    Clin Drug Investig; 2002 Sep; 22(9):633-638. PubMed ID: 29492857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency.
    Juul A; Bernasconi S; Clayton PE; Kiess W; DeMuinck-Keizer Schrama S;
    Horm Res; 2002; 58(5):233-41. PubMed ID: 12401943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.
    Sävendahl L; Maes M; Albertsson-Wikland K; Borgström B; Carel JC; Henrard S; Speybroeck N; Thomas M; Zandwijken G; Hokken-Koelega A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E213-7. PubMed ID: 22238393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children.
    Schena L; Meazza C; Pagani S; Paganelli V; Bozzola E; Tinelli C; Buzi F; Bozzola M
    J Pediatr Endocrinol Metab; 2017 Feb; 30(2):197-201. PubMed ID: 28099132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broad variability in pharmacokinetics of GH following rhGH injections in children.
    Lundberg E; Andersson B; Kriström B; Rosberg S; Albertsson-Wikland K
    Growth Horm IGF Res; 2018 Jun; 40():61-68. PubMed ID: 29422321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency.
    Link K; Bülow B; Westman K; Salmonsson EC; Eskilsson J; Erfurth EM
    Clin Endocrinol (Oxf); 2001 Dec; 55(6):741-8. PubMed ID: 11895215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.